Difference between revisions of "Peginterferon alfa-2a (Pegasys)"
m |
m |
||
| Line 29: | Line 29: | ||
[[Category:Pegylated medications]] | [[Category:Pegylated medications]] | ||
| − | [[Category: | + | [[Category:Interferon alfas]] |
[[Category:Chronic myeloid leukemia medications]] | [[Category:Chronic myeloid leukemia medications]] | ||
Revision as of 14:11, 1 August 2023
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood. Pegylation results in a much longer half-life compared to Interferon alfa-2a (Roferon-A).[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2002-10-16: Initial approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa.
History of changes in EMA indication
- 2001-07-05: EURD
Also known as
- Brand name: Pegasys